Randomization of Botox for Stent Pain and Irritative Voiding Symptoms

NCT ID: NCT02078895

Last Updated: 2018-08-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2017-02-28

Brief Summary

Botulinum toxin type A (Botox A) has shown great success in treating certain urologic conditions. A recent study has documented that Botox injected around the ureteral orifice (or place where the tube that connects the kidney to the bladder enters the bladder), during placement of a ureteral stent (small rubber tube that facilitate drainage of urine from the kidney to the bladder), resulted in a marked decline in the amount of stent pain experienced by patients. This finding was quite remarkable as stents are commonly used in many Urologic conditions, and these stents produce a remarkable degree of patient discomfort. Despite the great improvement in pain reduction, the irritative voiding symptoms [frequent need to void, urgency, burning with urination (dysuria) or nighttime voiding (nocturia)] were not ameliorated by the Botox injections in the ureteral orifice. However, it has already been well documented that in other clinical settings, administrations of Botox into the bladder muscle, has been shown to reduce these irritative symptoms.

The objective of the study is to determine if pain and irritative lower urinary tract symptoms related to ureteral stent placement will improve after the injection of Botox around the ureteral orifice and in the bladder itself.

Detailed Description

The objective of this prospective randomized single blinded controlled pilot study for patients undergoing unilateral ureteral stent insertion for benign urologic conditions is to determine if pain and irritative lower urinary tract symptoms (frequency, urgency, dysuria, nocturia) related to ureteral stent placement will improve after the injection of intradetrusor Botox (BTX) A.

The effects of BTX have been used for a number of medicinal purposes, including reducing wrinkles, migraine headaches, and excessive sweating. The use of BTX in urology and, more specifically, the lower urinary tract, is increasing. Botox is currently actively being used as a treatment strategy for use in Urologic conditions including neurogenic and non-neurogenic overactive bladder (OAB), detrusor sphincter dyssynergia, interstitial cystitis, urinary retention, and prostate disorders.

BTX serotypes. The seven distinct serotypes of BTX are designated A, B, C1, E, F, and G; BTX-A (Botox [Allergan, Inc., Irvine, Calif] and Dysport [Ipsen, Inc., Europe]) and BTX-B (Myobloc (Solstice Neurosciences, Inc., Malvern, Pa) are available commercially. Each serotype of botulinum toxin works by inhibiting the release of neurotransmitters, most notably acetylcholine, from the presynaptic neuromuscular junction (2). The result is inhibition of muscular contractions and paralysis.

In August 2011, the FDA recently approved the use of Botox injections for urinary incontinence secondary to neurogenic overactive bladder, a condition defined as unihibited bladder contractions causing voiding and creating symptoms of urinary frequency. The cause of the neurogenic overactive bladder in the patients studied was spinal cord injury and multiple sclerosis. Numerous prospective clinical trials have demonstrated a statistically significant difference of symptoms in patients receiving Botox injections into the overactive detrusor muscle compared to placebo groups. Botox injections were found to effectively relieve urinary incontinence and urinary frequency for a nine-month duration.

As part of standard clinical care, intravesical injection of Botox is currently used to ameliorate voiding symptoms in conditions where patients experience severe irritative symptoms and is currently seeking FDA approval for the treatment of overactive bladder in patients without a neurologic etiology. As a follow up study, we will evaluate the efficacy of combined periureteral and intravesical Botox injection for reduction of pain and irritative voiding

This is a prospective randomized single blinded controlled study for patients undergoing unilateral ureteral stent insertion for a benign urologic conditions is to determine if pain and irritative lower urinary tract symptoms (frequency, urgency, dysuria, nocturia) related to ureteral stent placement will improve after the injection of intradetrusor Botox A.

Study in detail:

All patients will be informed regarding the content of the study and informed consent will be obtained. Patients who require stent placement will be screened based on their past medical history and will be included in the study if they do not fit any of the exclusion criteria. The participation in the study will require 3 visits in addition to pre-op visit when the consent will be obtained: stent placement, stent removal, and 2 week post-op follow up. Patients will only have one pre-operative visit prior to ureteral stent placement. Patients will be randomized to one of two groups, experimental and placebo. The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A. The placebo group will involve a ureteral stent placement with no injection. Based on a randomization sequence from an electronic randomizer, patients will be placed in either Botox injection group or placebo (no injection) group. Patients will be consented at the pre-operative visit, which is usually up to seven days prior to the procedure. After informed consent is obtained, patients will be asked to complete a visual analog pain scale and a ureteral stent symptom questionnaire which can either be turned in during the pre-operative visit or alternatively, if the patient prefers to review the study prior to deciding to participate, can be turned in during the day of stent placement in the pre-operative area at UC Irvine Douglas Hospital before the procedure start time, giving the patient ample time to consider study participation. Baseline post-void residual will also be taken at the pre-operative visit. All stents will be inserted in a retrograde fashion as per standard of care. As standard of care, retrograde contrast injection following the procedure will be done to assess ureteral and renal anatomy. Jaime Landman, MD., and Gamal Ghoniem, MD., will be administering all Botox injections. Three 1mL Botox A injections (10U/mL) will be placed medial, lateral, and inferior to the ureteral orifice. Fourteen 1mL injections (5U/mL) will be placed into the detrusor muscle: three injections at the trigone avoiding the bladder neck, away from the peri-ureteral injections (10U/mL), and eleven injections distributed evenly across the remainder of the bladder. A total of 100 units (1 vial) of Botox A will be used per patient. 100 units of Botox A will be diluted with 10cc's of 0.9% PFNS, 3 cc's will be drawn for the peri-ureteral injections (30 units), then 7 ccs of 0.9% PFNS will be added to the vial to bring to 14cc's. The rest of the Botox A (70u) will be injected into the detrusor muscle.

Procedures will be planned for day surgeries and will be given one pre-operative dose of Kefzol for urinary tract infection prophylaxis as standard of care to all patients. The patient will subsequently be evaluated one hour after the procedure in the recovery room with a visual analog pain scale only. Subsequently, two post-operative evaluations will occur: On the day of stent removal, usually post-operative days (POD) 3 - 9, and POD 14 follow up, The patient will also be assessed during the second follow-up evaluation on POD's 3 - 9 for the possibility of urinary tract infection or urinary retention. A post-void residual will be taken during the 2 week follow-up to assess for urinary retention. On POD 14 visit, a USSQ, medication diary, visual pain analog scale will be collected from the patient. Post-operative evaluation will consist of a visual analog pain scale and a ureteral stent symptom questionnaire (USSQ) to assess pain, lower urinary tract symptoms, and quality of life. In addition, a narcotic diary will be kept by patients to determine the quantity and duration of oral narcotic required during the time the stent is in place. The narcotic diary is important in the study to assess the pain the patient is experiencing in addition to the visual pain analog scale that will be used. A standardized post-operative pain regimen will include Percocet (5mg Oxycodone/325mg Acetominophen) 1 - 2 tablets prn every 4 hours. Pain regimen of Percocet is standard of care and will not be used specifically for research purposes.

Conditions

Lower Urinary Tract Discomfort; Stent Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Botox

The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.

Group Type: EXPERIMENTAL

Botox

Intervention Type: DRUG

Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A

Control

The control group will involve a ureteral stent placement with no injection.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Botox

Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A

Intervention Type: DRUG

Other Intervention Names

Botulinum Toxin Type A

Eligibility Criteria

Inclusion Criteria

• Patients requiring unilateral ureteral stent insertion
• Age > 18
• Renal/ureteral stones (single or multiple)
• Ureteral strictures
• Surveillance ureterscopy
• Willing and able to consent
• Willing and able to complete study questionnaires/diaries
• Willing to use CIC to empty the bladder at any time after study treatment if it is determined to be necessary by the investigator

Exclusion Criteria

• History of malignancy
• Patients on medical therapy for benign prostatic hyperplasia (alpha blocker and/or 5alpha reductase inhibitor)
• Patients taking muscarinic-receptor antagonists (Ex. detrol, ditropan etc.)
• Patients who have an interstim sacral neuromodulator
• History of urinary retention
• Neurogenic or non-neurogenic detrusor overactivity
• Pregnancy
• Solitary kidney
• Insulin dependent Diabetes Mellitus (Uncontrolled Diabetes (HbA1c > 8))
• Neuropathy
• History of transplant kidney
• History of narcotic abuse or chronic pain
• Anatomic bladder/ureteral abnormality
• Previous cystectomy/urinary diversion
• Conditions necessitating bilateral ureteral stents
• History of Interstitial cystitis
• Patients with a post-void residual volume of > 100ml
• Patients with history of urinary retention
• Patients with active urinary tract infection
• Patients with history of chronic urinary tract infections
• Patients with concomitant use of any botulinum toxin within 3 months or any urological use of botulinum toxin in the past
• Patients with active genital infection, other than genital warts, either concurrently or within 4 weeks prior to screening
• Patients with concurrent or previously uninvestigated hematuria within 6 months prior to screening. -Patients with investigated hematuria may have entered the study if urological/renal pathology had been ruled out to the satisfaction of the investigator
• Patients with hemophilia, or other clotting factor deficiencies, or disorders that cause bleeding diathesis Patients with a known allergy or sensitivity to any botulinum toxin preparation (including study medication preparation), anesthetics, or antibiotics used during the study
• Patients with any medical condition that may have put them at increased risk with exposure to Botox including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of California, Irvine

OTHER

Sponsor Role: lead

Responsible Party

Jaime Landman

Department of Urology Chair

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jaime Landman, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Irvine Department of Urology

Locations

University of California, Irvine Medical Center

Orange, California, United States

Countries

United States

References

Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, Landman J. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010 Feb;183(2):598-602. doi: 10.1016/j.juro.2009.10.021. Epub 2009 Dec 16.

Reference Type: BACKGROUND

PMID: 20018320 (View on PubMed)

Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-68.

Reference Type: BACKGROUND

PMID: 9826987 (View on PubMed)

Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, Bard R, Valiquette L, Baverstock R, Carr L, Radomski S. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011 Jun;185(6):2229-35. doi: 10.1016/j.juro.2011.02.004. Epub 2011 Apr 16.

Reference Type: BACKGROUND

PMID: 21497851 (View on PubMed)

Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol. 2008 Jul;54(1):181-7. doi: 10.1016/j.eururo.2007.12.029. Epub 2007 Dec 26.

Reference Type: BACKGROUND

PMID: 18191323 (View on PubMed)

Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006 Jul;176(1):177-85. doi: 10.1016/S0022-5347(06)00590-8.

Reference Type: BACKGROUND

PMID: 16753396 (View on PubMed)

Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology. 2004 Jun;63(6):1071-5. doi: 10.1016/j.urology.2004.01.041.

Reference Type: BACKGROUND

PMID: 15183952 (View on PubMed)

Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Dec;14(6):424-6. doi: 10.1007/s00192-003-1099-3. Epub 2003 Nov 25.

Reference Type: BACKGROUND

PMID: 14677005 (View on PubMed)

Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, Shah PJ, Malone-Lee J. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005 Nov;174(5):1873-7; discussion 1877. doi: 10.1097/01.ju.0000177477.83991.88.

Reference Type: BACKGROUND

PMID: 16217327 (View on PubMed)

Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000 Sep;164(3 Pt 1):692-7. doi: 10.1097/00005392-200009010-00018.

Reference Type: BACKGROUND

PMID: 10953127 (View on PubMed)

Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdorfer H, Gocking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004 Apr;45(4):510-5. doi: 10.1016/j.eururo.2003.12.004.

Reference Type: BACKGROUND

PMID: 15041117 (View on PubMed)

Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.

Reference Type: BACKGROUND

PMID: 19233423 (View on PubMed)

Duvdevani M, Chew BH, Denstedt JD. Minimizing symptoms in patients with ureteric stents. Curr Opin Urol. 2006 Mar;16(2):77-82. doi: 10.1097/01.mou.0000193375.29942.0f.

Reference Type: BACKGROUND

PMID: 16479208 (View on PubMed)

Beiko DT, Knudsen BE, Denstedt JD. Advances in ureteral stent design. J Endourol. 2003 May;17(4):195-9. doi: 10.1089/089277903765444294.

Reference Type: BACKGROUND

PMID: 12816579 (View on PubMed)

Chew BH, Duvdevani M, Denstedt JD. New developments in ureteral stent design, materials and coatings. Expert Rev Med Devices. 2006 May;3(3):395-403. doi: 10.1586/17434440.3.3.395.

Reference Type: BACKGROUND

PMID: 16681460 (View on PubMed)

Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003 Mar;169(3):1060-4. doi: 10.1097/01.ju.0000049198.53424.1d.

Reference Type: BACKGROUND

PMID: 12576846 (View on PubMed)

Other Identifiers

2013-9702

Identifier Type: -

Identifier Source: org_study_id